Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and gives insights into the International Psoriasis Council presentations regarding the pathogenesis of psoriasis.
Study shows risankizumab is effective regardless of prior biologic treatment
According to a recent study, risankizumab is effective at achieving skin clearance in moderate-to-severe plaque psoriasis patients regardless of whether they have been treated with biologics previously.
Study shows race may not be associated with access to PsO biologics
According to a recent study, race and ethnicity may not be associated with access to biologics for psoriasis patients in the United States.
QoL impairment and worse symptoms in PsO, AD linked to differing views on disease severity
According to a new study, psoriasis and atopic dermatitis (AD) patients may have differing views on disease severity, a phenomenon known as discordant severity grading. This phenomenon has been linked to higher symptom expression and greater quality of life (QoL) impairment.
Majority of psoriasis patients prefer home narrowband UV-B therapy over in-office therapy
Approximately two thirds of psoriasis patients who received home narrowband ultraviolet-B (UV-B) therapy did not use systemic therapy or in-office UV-B therapy for one year after starting at-home treatment, according to a new study.
Study shows hypertension, metabolic syndrome, waist circumference can increase psoriasis risk
According to a recent study, investigators have linked metabolic syndrome, waist circumference, and hypertension to increased psoriasis risk.
Psoriasis patients across all Fitzpatrick skin types respond well to CAL/BDP cream
According to a new study, plaque psoriasis patients with Fitzpatrick skin types IV through VI treated with calciprotriene/betamethasone dipropionate (CAL/BDP) cream respond in a similar manner as those with Fitzpatrick skin types I through III.
Study shows lower fertility rates in patients with moderate-to-severe plaque psoriasis
According to a recent study, patients with moderate-to-severe plaque psoriasis have lower fertility rates and higher risk of pregnancy loss than women without psoriasis.
Tildrakizumab linked to improved QoL, sleep in plaque psoriasis patients
According to a new study, tildrakizumab is linked to improved quality of life (QoL) and sleep in patients with moderate-to-severe plaque psoriasis.
New study shows biologics not linked to adverse events in pregnant psoriasis patients
According to a new study, exposure to biologics during pregnancy and conception does not increase the risk of adverse events in pregnant psoriasis patients.
HealthMinute.TV 